Skip to main content
Premium Trial:

Request an Annual Quote

Novartis Extends License Agreement with Compugen

NEW YORK, June 16 - Novartis Pharma has extended its license for Compugen's LEADS computational biology platform for an additional year, Compugen said today.

 

The collaboration between the two firms, which began in August 2001, will also be expanded to include DNA probe design. Under the renewed agreement, Compugen said it would design a genome-wide collection of DNA probes for Novartis based on data from its transcriptome analysis research, which accounts for alternative splicing and naturally occurring antisense.

 

The additional year will complete the maximum three-year term of the original agreement between the companies.